Can allo-SCT with RIC cure ATLL? Long-term survivors with excellent PS and with heterogenous HTLV-1 proviral load level
Main Authors: | Choi Ilseung, Utsunomiya Atae, Tanosaki Ryuji, Uike Naokuni, Okamura Jun |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-06-01
|
Series: | Retrovirology |
Similar Items
-
Arsenic trioxyde in the treatment of HTLV1 associated ATLL
by: deThe Hugue, et al.
Published: (2011-06-01) -
Editorial: Strengths and Challenges of Allo-SCT in the Modern Era
by: Michele Malagola, et al.
Published: (2022-02-01) -
Identification and characterization of a novel enhancer in the HTLV-1 proviral genome
by: Misaki Matsuo, et al.
Published: (2022-05-01) -
The Emerging Role of miRNAs in HTLV-1 Infection and ATLL Pathogenesis
by: Ramona Moles, et al.
Published: (2015-07-01) -
Inhibition of ABL1 tyrosine kinase reduces HTLV-1 proviral loads in peripheral blood mononuclear cells from patients with HTLV-1-associated myelopathy/tropical spastic paraparesis.
by: Daisuke Kodama, et al.
Published: (2020-07-01)